Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment. (TALISMAN)

Ipsen

Status: Completed

Conditions: Prostate Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT04593420

A-FR-52014-241

Details and patient eligibility

About

The purpose of the protocol is to describe the proportion of subjects treated continuously with triptorelin during 12 months following treatment initiation. This study will take place at 187 locations (approximately) in France.

Enrollment: 817 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 18 years old
• Histologically confirmed prostate cancer
• Triptorelin to be initiated in its labelled indication for a planned total duration of at least 12 months; decision to start triptorelin was made voluntarily by the physician as part of routine medical practice, prior to the inclusion in the study
• Ability to understand and complete questionnaire,

Exclusion criteria

• Previously received a hormonal therapy during the last 6 months before inclusion,
• Simultaneously participates in a clinical trial.